Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30
Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational…
Innovent’s Once-Weekly Oral GLP-1 IBI3042 Gets NMPA IND Clearance for Obesity
Innovent Biologics has received clearance from China’s National Medical Products Administration (NMPA) to begin clinical development of IBI3042, a potentially first-in-class once-weekly oral small-molecule GLP-1 receptor agonist, marking another…